Codiak Biosciences Stock News

Codiak Biosciences Inc (CDAK) shares closed 5.3% lower than its previous 52 week low, giving the company a market cap of $251M. The stock is currently down 65.2% year-to-date, down 51.1% over the past 12 months, and down 7.3% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 13.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 119.4% The company's stock price performance over the past 12 months lags the peer average by 63.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Codiak BioSciences (NASDAQ:CDAK) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Volatility and Risk Codiak BioSciences has a beta of 4.13, suggesting that its stock price is []

Codiak BioSciences (NASDAQ:CDAK) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership. Risk & Volatility Codiak BioSciences has a beta of 4.13, indicating that its share price is []

Codiak BioSciences (NASDAQ:CDAK) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations. Insider and Institutional Ownership 62.9% of Codiak BioSciences shares are owned by institutional investors. Comparatively, 96.1% []

Codiak BioSciences Inc (NASDAQ: CDAK ) announced new preclinical data from its exoVACC exosome-based vaccine platform. The data showed that the COVID-19 vaccine candidate generated a comprehensive immune response conferring both antibody and T cell-mediated immunity. The data showed that an exosome carrying the SARS-CoV-2 receptor-binding domain (RBD) induced an Full story available on Benzinga.com

The stock price of Codiak BioSciences Inc (NASDAQ: CDAK) increased by over 8% during intraday trading today. This is why it happened.

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ne

Virtu Financial LLC purchased a new position in Codiak BioSciences, Inc. (NASDAQ:CDAK) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,510 shares of the companys stock, valued at approximately $213,000. Virtu Financial LLC owned 0.05% of Codiak BioSciences at the end of []

Virtu Financial LLC bought a new position in Codiak BioSciences, Inc. (NASDAQ:CDAK) during the second quarter, Holdings Channel reports. The fund bought 11,510 shares of the companys stock, valued at approximately $213,000. Several other large investors have also added to or reduced their stakes in CDAK. Legal & General Group Plc grew its position in []

Codiak BioSciences Inc (NASDAQ: CDAK ) announced initial data for exoSTING currently in a Phase 1/2 trial as a single agent for the treatment of multiple solid tumors. ExoSTING is an engineered exosome therapeutic candidate. In the first three dose cohorts of the trial, participants treated with exoSTING showed evidence Full story available on Benzinga.com

exoSTING resulted in localized STING pathway activation and dose-dependent immune activation Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 Codiak to host conference call and webcast today at 8:00 am ET CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK ), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced positive initial data for exoSTING, a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors. "We are excited to see that the initial foundational data from our exoSTING program are consistent with the pharmacologic activity that we observed with the candidate preclinically, and point to a differentiated mechanism of action afforded by the engineered exosome-based delivery of the STING agonist," said Doug Williams, PhD, CEO of Codiak. "The targeted delivery and tumor retention observed so far appear to effectively engage the STING pathway, and at tested doses, exoSTING was well tolerated and showed initial signals of clinical activity.

Codiak BioSciences Inc (NASDAQ: CDAK) announced initial data for exoSTING currently in a Phase 1/2 trial as a single agent for the treatment of multiple solid tumors. ExoSTING is an engineered exos

Geode Capital Management LLC lifted its stake in shares of Codiak BioSciences, Inc. (NASDAQ:CDAK) by 67.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 206,577 shares of the companys stock after acquiring an additional 82,905 shares during the period. Geode Capital []

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of -2.11% and -59.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the